Pfizer Inc.'s proposed osteoporosis drug could be useful for postmenopausal women and the benefits outweigh risks such as blood clots, an expert advisory panel said on Monday.

However, the drug, Fablyn (lasofoxifene tartrate) should be restricted to women at high risk of fracture or those who fail other treatments

Researchers have found that sex may be mostly in a person's head.

A new study finds that most cervical cancer survivors report satisfying sex lives, which challenges the public perceptions on what role hormones play in sexual activity. That's because surgical intervention usually reduces, or eliminates, a key hormone involved in female sexuality

A drug from Pfizer and Ligand Pharmaceuticals effectively treats osteoporosis but it may increase the chances of death from cancer or stroke, the U.S. Food and Drug Administration (FDA) noted Thursday.

Pfizer's Fablyn is taken once daily as a tablet to prevent fractures in postmenopausal women with osteoporosis. The drug lasofoxifene tartrate or Fablyn was rejected by the FDA in September 2005 as a medicine to prevent osteoporosis

An experimental drug called pegloticase lowered levels of uric acid in the blood to target levels within a few hours in most gout patients that could help them cope with the painful condition.

Current treatments for gout include use of drugs such as allopurinol and probenecid, which reduce blood levels of uric acid. However, some people with difficult-to-treat gout cannot tolerate medications or are not helped by drugs. Pegloticase is more soluble in blood and easier to excrete

The makers of the type 2 diabetes drug Byetta reported deaths of four more people who'd been taking the medication, bringing the total to six.

Last week, Eli Lilly & Co. and Amylin Pharmaceuticals Inc.'s diabetes drug Byetta has previously been linked to two deaths and four hospitalizations. All the patients are reported to have died after developing acute pancreatitis, the manufacturer said. The condition can cause nausea, vomiting and abdominal pain